Muscarinic Acetylcholine Receptor M1 Antagonists - Pipeline Insight, 2020

Publisher Name :
Date: 24-Nov-2020
No. of pages: 70
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2020," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Muscarinic Acetylcholine Receptor M1 Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Muscarinic Acetylcholine Receptor M1 Antagonists Understanding

Muscarinic Acetylcholine Receptor M1 Antagonists: Overview

The mAChRs are a sub-class of the G-protein-coupled receptors (GPCRs) family, comprising 5 subtypes (M1-M5). M1, M3, and M5 are coupled with the Gq protein and, via phospholipase C signaling pathway, generate cytosolic calcium transients; M2 and M4, on the other hand, couple with the Gi protein inhibiting the adenylyl cyclase. While obtaining mAChRs subtype-selective ligands is a primary goal in drug development previous attempts have failed due to the highly conserved structure of the orthosteric binding site across the muscarinic receptor family members.

Muscarinic Acetylcholine Receptor M1 Antagonists Emerging Drugs Chapters

This segment of the Muscarinic Acetylcholine Receptor M1 Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Muscarinic Acetylcholine Receptor M1 Antagonists Emerging Drugs

- KarXT - Karuna Therapeutics

Karuna Therapeutics lead product candidate, KarXT, selectively activates muscarinic acetylcholine receptors in the brain to unlock the therapeutic potential of xanomeline, which previously demonstrated significant benefits in Phase 2 studies in schizophrenia and Alzheimer's.

Further product details are provided in the report……..

Muscarinic Acetylcholine Receptor M1 Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Muscarinic Acetylcholine Receptor M1 Antagonists drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players working on Muscarinic Acetylcholine Receptor M1 Antagonists

There are approx. 20+ key companies which are developing the Muscarinic Acetylcholine Receptor M1 Antagonists. The companies which have their Muscarinic Acetylcholine Receptor M1 Antagonists drug candidates in the most advanced stage, i.e. phase II include, Karuna Therapeutics.

- Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

- Late-stage products (Phase III and

- Mid-stage products (Phase II and

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Muscarinic Acetylcholine Receptor M1 Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Infusion

- Intradermal

- Intramuscular

- Intranasal

- Intravaginal

- Oral

- Parenteral

- Subcutaneous

- Topical.

- Molecule Type

Products have been categorized under various Molecule types such as

- Vaccines

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Muscarinic Acetylcholine Receptor M1 Antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Muscarinic Acetylcholine Receptor M1 Antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Muscarinic Acetylcholine Receptor M1 Antagonists drugs.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Muscarinic Acetylcholine Receptor M1 Antagonists R&D. The therapies under development are focused on novel approaches for Muscarinic Acetylcholine Receptor M1 Antagonists.

Muscarinic Acetylcholine Receptor M1 Antagonists Report Insights

- Muscarinic Acetylcholine Receptor M1 Antagonists Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Muscarinic Acetylcholine Receptor M1 Antagonists Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

- How many companies are developing Muscarinic Acetylcholine Receptor M1 Antagonists drugs?

- How many Muscarinic Acetylcholine Receptor M1 Antagonists drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for Muscarinic Acetylcholine Receptor M1 Antagonists?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Muscarinic Acetylcholine Receptor M1 Antagonists therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Muscarinic Acetylcholine Receptor M1 Antagonists and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Karuna Therapeutics

Key Products

- KarXT

Muscarinic Acetylcholine Receptor M1 Antagonists - Pipeline Insight, 2020

Table of Contents

Introduction
Executive Summary
Muscarinic Acetylcholine Receptor M1 Antagonists: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Muscarinic Acetylcholine Receptor M1 Antagonists - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• Muscarinic Acetylcholine Receptor M1 Antagonists companies' collaborations, Licensing, Acquisition -Deal Value Trends
Muscarinic Acetylcholine Receptor M1 Antagonists Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
• Comparative Analysis
KarXT - Karuna Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Muscarinic Acetylcholine Receptor M1 Antagonists Key Companies
Muscarinic Acetylcholine Receptor M1 Antagonists Key Products
Muscarinic Acetylcholine Receptor M1 Antagonists- Unmet Needs
Muscarinic Acetylcholine Receptor M1 Antagonists- Market Drivers and Barriers
Muscarinic Acetylcholine Receptor M1 Antagonists- Future Perspectives and Conclusion
Muscarinic Acetylcholine Receptor M1 Antagonists Analyst Views
Muscarinic Acetylcholine Receptor M1 Antagonists Key Companies
Appendix


List of Tables

Table 1 Total Products for Muscarinic Acetylcholine Receptor M1 Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products


List of Figures

Figure 1 Total Products for Muscarinic Acetylcholine Receptor M1 Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Recombinant Human Erythropoietin (rhEPO) Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 99
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - ESRD - Cancer - HIV - Wounds and Neural Disease Segment by Application - Hospi......
  • Global rhEPO Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 97
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - ESRD - Cancer - HIV - Wounds and neural disease Segment by Application - Hospi......
  • Global Rhematoid Arthritis Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 94
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Pharmaceuticals - Biopharmaceuticals Segment by Application - Prescription - OTC......
  • Global Chronic Obstructive Pulmonary Disease Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 118
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Inhalers - Nebulizers Segment by Application - Emphysema - Chronic Bronchitis ......
  • Global Chronic Lymphocytic Leukemia Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 121
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Acutemyeloid (ormyelogenous)leukemia (AML) - Chronicmyeloid (ormyelogenous)leukemia (CML) - Acutelymphocyti......
  • Global Chemotherapy-induced Nausea and Vomiting Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 93
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - 5-HT3 Inhibitors - NK1 Inhibitors - Other Segment by Application - Highly Emetogenic ......
  • Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 120
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Aloxi (Palonosetron) - Kytril Generic (Granisetron) - Emend (Aprepitant) - Akynzeo (Netupitant-Palon......
  • Global ß-blockers Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 122
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Nonselective Agents - Selective Agents Segment by Application - Abnormal Heart Rhythms......
  • Global a-adrenoreceptor Antagonists Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 116
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Non-selective Antagonists - Selective Antagonists Segment by Application - Hypertension......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs